HCM Hutchison China Meditech Ltd Sponsored ADR

Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences

Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“”) (Nasdaq/AIM: HCM) today announces that Mr. Christian Hogg, Chief Executive Officer of Chi-Med, will present or participate in the following virtual conferences:

  • The 15th Citi China Investor Conference on Thursday, November 5, 2020; and



  • The “China Summit Survey Results: Where is the "Bridge to Innovation" Headed?” Panel as part of the BioCentury-BayHelix 7th China Healthcare Summit on Monday, November 9, 2020.

Members of the management team will attend the above conferences in one-on-one meetings, and will also attend the following virtual investor conferences at certain times:

  • The Bank of America 2020 China Conference held from November 2 to 13, 2020;



  • The Goldman Sachs Asia Pacific Healthcare Forum held from November 16 to 18, 2020;



  • The 11th Annual Jefferies Global Healthcare Conference held from November 17 to 19, 2020;



  • The Morgan Stanley Asia Pacific Summit held from November 18 to 20, 2020; and



  • The Piper Sandler 32nd Annual Healthcare Conference held from December 1 to 3, 2020.

Further information are available at in the Shareholder Information section under “.”

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med’s filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

Investor Enquiries 
Mark Lee, Senior Vice President+852 2121 8200
Annie Cheng, Vice President+1 (973) 567 3786
  
Media Enquiries 
Americas – Brad Miles, Solebury Trout+1 (917) 570 7340 (Mobile)

Europe – Ben Atwell / Alex Shaw, FTI Consulting+44 20 3727 1030 / +44 7771 913 902 (Mobile) /

+44 7779 545 055 (Mobile)

Asia – Joseph Chi Lo / Zhou Yi, Brunswick+852 9850 5033 (Mobile), /

+852 9783 6894 (Mobile),
  
Nominated Advisor 
Freddy Crossley / Atholl Tweedie,

Panmure Gordon (UK) Limited
+44 (20) 7886 2500

 

EN
30/10/2020

Underlying

Reports on Hutchison China Meditech Ltd Sponsored ADR

Franc Gregori ... (+2)
  • Franc Gregori
  • Lala Gregorek

Trinity Delta Lighthouse: HUTCHMED

Trinity Delta view: HUTCHMED’s sustainable profitability aim is underpinned by continued commercial and R&D execution. Geographic expansion ex-China, new indications for current China products, and potential new product approvals will support near-term growth, while M&A and/or in-licensing have a role in the mid-term. Accelerated investment in the highly attractive ATTC platform, which could address a wide range of oncology indications with sizeable market potential, should drive longer-term pro...

 PRESS RELEASE

Intended Retirement of Independent Non-executive Director and changes ...

Intended Retirement of Independent Non-executive Director and changes of composition of board committees HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Mok Shu Kam, Tony has informed the Company that he would not seek re-election after retiring from the Board at the forthcoming annual general meeting of the Company to be held on May 12, 2026 (“AGM”). Professor Mok has served as an Independent Non-executive Director of the Company for more than eight ...

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

HUTCHMED (China) (13 HK): 2025: Results In Line, Sales Recovery To Con...

2025 results were in line. Total revenue declined 13% yoy, but Fruquintinib’s in-market sales rebounded significantly hoh driven by continuous overseas growth and positive impact from sales restructuring in China. It targets oncology/immunology revenue of US$330m-450m supported by continued sales recovery. Seeing smooth R&D progress, we expect a new wave of market approvals to fuel growth for HUTCHMED in the years ahead. Maintain BUY with a lower target price of HK$26.00 reflecting rising geopol...

Bella Lu Yifei ... (+10)
  • Bella Lu Yifei
  • Carol Dou Xiao Qin
  • Claire Wang Kelai
  • Gigi Cheuk
  • Joyce Chu
  • Julia Pan Mengyao
  • Kate Luang
  • Ken Lee
  • Sunny Chen
  • Tham Mun Hon

Greater China Daily: Friday, March 6, 2026

Top Stories Economics | China China set a 2026 GDP growth target of 4.5-5.0% yoy, in line with expectations, while maintaining a 4% fiscal deficit ratio. Fiscal policy remains the main growth driver, supported by Rmb4.4t in local government special bonds and Rmb1.3t in ultra-long treasury bonds, while monetary policy stays accommodative. Policy priorities focus on AI+, New Quality Productive Forces, industrial upgrading, and targeted consumption support, alongside welfare improvements and the g...

 PRESS RELEASE

HUTCHMED Reports 2025 Full Year Results and Business Updates

HUTCHMED Reports 2025 Full Year Results and Business Updates — Geographic expansion driving ex-China sales growth; indication expansions driving China sales growth — — $457 million net income, driven by profitable core operations and non-core disposal — — Rapidly progressing groundbreaking ATTC technology, a source of novel drug candidates with broad therapeutic potential — — Pursuing potential opportunities for partnering ATTC candidates with multinational pharmaceutical companies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J. , March 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Li...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch